Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Ranee Mehra

Email
Center AffiliationsMolecular Therapeutics

Publications (65) (print view)

paginate
Beck TN, Smith CH, Flieder DB, Galloway TJ, Ridge JA, Golemis EA, Mehra R. Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head & neck. 2017 Mar;39(3):E34-E39.   PMCID: PMC5439525
Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. Journal for immunotherapy of cancer. 2017 Jan;5:40.   PMCID: PMC5433051
Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. The oncologist. 2017 Jun 26;22(10):1232-7.   PMCID: PMC5634771
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun. 2017 Nov 24;8(1):1772.   PMCID: PMC5701248
Ramakodi MP, Devarajan K, Blackman E, Gibbs D, Luce D, Deloumeaux J, Duflo S, Liu JC, Mehra R, Kulathinal RJ, Ragin CC. Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase beta and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma. Cancer. 2017 Mar;123(5):849-60.   PMCID: PMC5319896
Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol. 2017 Jun;12(6):932-42.
Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification. Ear, Nose and Throat Journal. 2017 Jul;96(7):E12-E18.
Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-negative Head and Neck Cancer. Mol Cancer Ther. 2016 Oct;15(10):2486-97.   PMCID: PMC5522587
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Sep 19;.
Dong Y, Li T, Churilla TM, Mehra R, Lango M, Bauman J, Ridge JA, Galloway TJ. Long-Term Toxicities in Survivors of Radiation Treatment for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E394.
Dziemianowicz M, Murphy CT, Devarajan K, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Evaluating the Impact of Node-Specific Growth in Patients With Node-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E368-E369.
Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget. 2016 Sep 08;7(42):68206-28.   PMCID: PMC5356550
Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Mar 10;17(4):452-63.   PMCID: PMC5063047
Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Moran K, Ridge JA. Impact of baseline patient-reported dysphagia on acute gastrostomy placement in patients with head and neck squamous cell carcinoma undergoing definitive radiation. Head & neck. 2016 Apr;38 Suppl 1:E1318-24.
Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States. J Clin Oncol. 2016 Jan 10;34(2):169-78.   PMCID: 4858932
Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States. J Clin Oncol. 2016 Jan 10;34(2):169-78.   PMCID: PMC4858932
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-65.
Shaikh T, Handorf EA, Murphy CT, Mehra R, Ridge JA, Galloway TJ. The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Dec;96(5):967-75.   PMCID: PMC5147736
Shaw AT, Spigel DR, Tan DS, Kim DW, Mehra R, Orlov S, Park K, Yu CJ, Mok T, Nishio M, Scagliotti G, Sutradhar S, Cesic D, Felip E. MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naive Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11s):S256.
Yoon S, Shaikh T, Ross EA, Bauman J, Borghaei H, Mehra R, Meyer JE, Hallman MA. Patterns and Predictors of Failure Following Definitive Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E477-E478.
Zibelman M, Mehra R. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol. 2016 Aug;39(4):396-406.
Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget. 2015 Aug 07;6(22):18863-74.   PMCID: 4662460
Chakraborty AK, Mehra R, Digiovanna MP. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer research. 2015 Mar;35(3):1243-50.
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Kaczmar J, Mehra R. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer. Ther Adv Respir Dis. 2015 Oct;9(5):236-41.
Kaczmar J, Mehra R. HPV-negative head and neck squamous cell carcinomas: how can we use the tumor protein signature?. Biomark Med. 2015 Mar;9(3):183-5.
Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer. Oral Oncol. 2015 Nov;51(11):1034-40.
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder DB, Ridge JA. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer. 2015 Apr 15;121(8):1204-13.
Pancari P, Mehra R. Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck. Surg Oncol Clin N Am. 2015 Jul;24(3):437-54.
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR. Multidisciplinary Therapy of Stage IIIA Non-Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation With or Without Surgery. Cancer control : journal of the Moffitt Cancer Center. 2014 Jan;21(1):57-62.
Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals of Oncology. 2014 Jul;25(7):1410-6.   PMCID: PMC4071756
Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep;32(25):2735-43.
Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clin Cancer Res. 2014 Oct;20(19):5041-51.   PMCID: Pmc4184913
Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & neck. 2014 Dec;36(12):1677-84.   PMCID: PMC3972378
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014 Mar 15;120(6):840-7.   PMCID: Pmc3951722
Ragin C, Obikoya-Malomo M, Kim S, Chen ZJ, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Liu HE, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. HPV-associated lung cancers: an international pooled analysis. Carcinogenesis. 2014 Jun;35(6):1267-75.   PMCID: PMC4043241
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. The New England journal of medicine. 2014 Mar 27;370(13):1189-97.   PMCID: PMC4079055
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.   PMCID: No NIH funds
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns. Head & neck. 2013 Feb;35(2):160-4.   PMCID: PMC 4037756
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li TY, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid : official journal of the American Thyroid Association. 2013 Sep;23(9):1099-105.   PMCID: PMC 3770240
Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases in head and neck cancer. Lancet Oncology. 2013 Sep;14(10):E425-E435.
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clin Cancer Res. 2013 Dec;19(23):6633-43.   PMCID: PMC 4045641
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013 Dec;19(23):6633-43.   PMCID: Pmc4045641
Sopka DM, Li TY, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in 'Low-Risk' squamous cell carcinoma of the oral tongue. Oral Oncology. 2013 Nov;49(11):1083-7.   PMCID: PMC4037753
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer discovery. 2013 Jan;3(1):96-111.   PMCID: PMC3546138
Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling". Science signaling. 2012 Jan;5(254):lc5.   PMCID: Comment
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 2012 Apr;18(7):2056-65.
Mehra R, Ang KK, Burtness B. Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol. 2012 Jul;22(3):194-7.   PMCID: not NIH funded
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. NONSURGICAL MANAGEMENT OF OROPHARYNGEAL, LARYNGEAL, AND HYPOPHARYNGEAL CANCER: THE FOX CHASE CANCER CENTER EXPERIENCE. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Oct;33(10):1433-40.   PMCID: Not NIH Funded
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 2011 Jul;29(19):2660-6.   PMCID: not NIH funded
Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates. 2011 Dec;14(6):260-79.   PMCID: PMC3195944
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen CH. INITIAL RESULTS OF A PHASE I DOSE-ESCALATION TRIAL OF CONCURRENT AND MAINTENANCE ERLOTINIB AND REIRRADIATION FOR RECURRENT AND NEW PRIMARY HEAD-AND-NECK CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):1020-5.   PMCID: not NIH funded
Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics. 2010 Jan;4:173-85.   PMCID: PMC2921255
Turaka A, Li TY, Sharma NK, Li LN, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):599-603.   PMCID: not NIH funded
Borghaei H, Mehra R, Simon G. Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Future Oncol. 2009 Feb;5(1):19-22.   PMCID: Comment - no NIH
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Mehra R, Cohen RB. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi.   PMCID: PMC2659655
Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50.
Mehra R, Cohen RB, Harari P. Targeted therapies in head and neck cancer. In: Small W, editor. Combining targeted biological agents with radiotherapy : current status and future directions. New York: Demos Medical Pub.; 2008. p. 107-38.
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Mehra R, Treat J. Part II: treatment of non-small-cell lung cancer: chemotherapy. In: Fishman AP, Elias JA, editors. Fishman's pulmonary diseases and disorders. New York: McGraw-Hill, Medical Pub. Division; 2008. p. 1867-82.
Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opin Biol Ther. 2006 Sep;6(9):951-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Ranee Mehra Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Monday, December 04, 2017